Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|December 20, 2024

Video Abstract: Diabetes, Cardiorenal, and Metabolic Multispecialty Practice Recommendations and Early Intensive Management of Cardio-Renal-Metabolic Disease

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Man having heart attack - dragonstock - stock.adobe.com

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

ByPearl Steinzor

July 22nd 2026

David Zhang

Challenges to Clinical Implementation of IPF Polygenic Risk Scores: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 22nd 2026

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

ByBrooke McCormick

July 22nd 2026

David Zhang

Real-World PRS Data Advance IPF Risk Prediction, Diagnosis: David Zhang, MD

BySabrina McCrear,David Zhang, MD

July 21st 2026

mantle cell lymphoma | Image: Perla Vicari / ASH Image Bank

Case Studies Focus on Glofitamab as Bridge to CAR T in MCL

July 20th 2026

Trending on AJMC

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Fifth Death Confirmed in NYC Legionnaires' Outbreak

FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC

Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial

Acalabrutinib-Venetoclax Combos Improve QOL, Safety by Age in CLL